Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs.
about
Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancerA comprehensive review on pharmacotherapeutics of herbal bioenhancersAntitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid LeukemiaITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humansMicro/nanofabricated platforms for oral drug deliveryEnhanced brain disposition and effects of Δ9-tetrahydrocannabinol in P-glycoprotein and breast cancer resistance protein knockout miceDexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrierKnowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug DiscoveryA structure-based design of new C2- and C13-substituted taxanes: tubulin binding affinities and extended quantitative structure-activity relationships using comparative binding energy (COMBINE) analysis.Botryllamides: natural product inhibitors of ABCG2A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models.Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrierEstrogen receptor beta signaling through phosphatase and tensin homolog/phosphoinositide 3-kinase/Akt/glycogen synthase kinase 3 down-regulates blood-brain barrier breast cancer resistance protein.ABC multidrug transporters: structure, function and role in chemoresistance.ATP-binding cassette efflux transporters in human placenta.Benzanilide-Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-Type ABCG2 Modulators.Characterisation and manipulation of docetaxel resistant prostate cancer cell lines.Breast cancer medications and vision: effects of treatments for early-stage disease.Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk.Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team upHistone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells.Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.Preclinical approaches to study the biology and treatment of brain metastases.Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel.Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment.The dual cyclooxygenase/5-lipoxygenase inhibitor licofelone attenuates p-glycoprotein-mediated drug resistance in the injured spinal cord.Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.Inhibiting kinases in malignant gliomas.Molecularly targeted therapies for malignant gliomas: advances and challenges.Morphine modulates doxorubicin uptake and improves efficacy of chemotherapy in an intracranial xenograft model of human glioblastomaBioenhancers from mother nature and their applicability in modern medicine.Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy.Antipsychotic drugs inhibit the function of breast cancer resistance protein.Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoproteinProdrug approaches for CNS deliveryPhRMA white paper on ADME pharmacogenomics.New structure-activity relationships of chalcone inhibitors of breast cancer resistance protein: polyspecificity toward inhibition and critical substitutions against cytotoxicity.P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer modelEngineering strategies to enhance nanoparticle-mediated oral delivery.
P2860
Q24621947-2A23FC51-0112-49FF-B95E-FA83901109F3Q24633680-A77B7DCB-9C49-4B72-83EC-AE098654E4FEQ24649780-4FA95EF3-BFFE-4D1B-B210-3F30E0B4AE5FQ26781539-D5CCCE8C-C020-4473-94F8-CEBEBDB35FAAQ27022933-B1DEA785-2E95-4129-A6A7-D1CC1B16ECECQ28083448-C35641F0-BC8F-4E84-B05B-A6ADB884FBF8Q28482464-4AADAD7C-29D4-437E-AF34-5C155BD5645AQ28572624-2BEE74F0-D905-4B2F-9D63-801159B63138Q28732740-9425488F-52E2-498D-8589-5C4B8216F6B7Q30607577-3CEEFA57-5244-4D6B-B9FA-440A2509B686Q33474489-B2EEC90F-7698-4538-8BE1-5888FF5AF0BBQ33484368-DA1A3EC9-8B5D-4EA4-BA44-57EC8D5DFCB1Q33900889-0E969185-6548-4E1F-BCCC-B9ABAAC27227Q34035224-CA3FDB48-27C4-4BBC-9D76-F4255C6EC4C5Q34586418-F2DBC175-FE17-43A8-8407-DF933FBABD5FQ34843023-B80D4390-E6BD-45CF-B965-6FE74E0D0D45Q35181940-FE49BF42-E867-498F-8DDF-3102899CC98FQ35462077-C9DC3CB4-A748-4C21-992E-82496633D67DQ35496778-1351E8C4-7989-4A79-A029-40C798F49FA2Q35641888-5F4DCFBE-88D3-4E7D-A2DF-9B3D4354B8F6Q35720625-4D130848-4EF8-4A93-9A37-328D5975D4C6Q35837565-D1850723-417F-4D90-8178-75D71F15037DQ35946822-08ED56EE-3158-493E-91A9-9F2A0871DEBCQ35967411-1A9A7CE1-36F6-4E2F-BFFC-FBD1135EE277Q36035404-B4FDCD39-07AD-44B0-A74B-E2566186ACDCQ36499234-1A50697D-482A-4B59-9E09-86D5D17EA42CQ36590671-472443E0-0D5F-4712-A0F2-E6936B15ABF9Q36613936-C4B03D78-1B65-4D85-92E7-2C22D341BD21Q36764876-D8265D9B-DC95-4537-B963-D083F87887A4Q36817109-1574DE60-EE49-4630-8FD0-0AAE278E1830Q36853871-AFA67547-4ABA-44E5-B85A-72BF398E325AQ36855754-7E97646D-0D61-4921-BC87-F58620B6920CQ37080236-D8F8D9E3-DDAD-4A85-90CD-26805C359FCFQ37087966-22E0F92E-8C9B-4BCF-9F76-43FAAC228DADQ37137438-648F9AD2-9C3C-433B-B847-D0086DA5781AQ37150860-27203A57-5A89-4C17-B630-43480FC0D94BQ37182212-B073AE4D-D93F-40FE-9B57-4B3E823D217DQ37221083-732B1DED-1CAD-4B20-A6F1-7A000FB19064Q37276052-2055E3AD-BDCB-40B6-8E10-4B67BCD02137Q37328673-C909DB1A-593D-4825-A130-7F91B3F8415B
P2860
Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Use of P-glycoprotein and BCRP ...... netration of anticancer drugs.
@ast
Use of P-glycoprotein and BCRP ...... netration of anticancer drugs.
@en
type
label
Use of P-glycoprotein and BCRP ...... netration of anticancer drugs.
@ast
Use of P-glycoprotein and BCRP ...... netration of anticancer drugs.
@en
prefLabel
Use of P-glycoprotein and BCRP ...... netration of anticancer drugs.
@ast
Use of P-glycoprotein and BCRP ...... netration of anticancer drugs.
@en
P2093
P1476
Use of P-glycoprotein and BCRP ...... netration of anticancer drugs.
@en
P2093
Jan H M Schellens
Jos H Beijnen
Pauline Breedveld
P356
10.1016/J.TIPS.2005.11.009
P577
2005-12-05T00:00:00Z